[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100591489":3},{"organization":4,"armGroups":7,"interventions":25,"overallOfficials":31,"centralContacts":38,"locations":48,"responsibleParty":72,"collaborators":31,"id":74,"slug":75,"hasResults":76,"nctId":77,"briefTitle":78,"officialTitle":78,"acronym":31,"eligibilityCriteria":79,"healthyVolunteers":76,"sex":80,"minAge":81,"maxAge":82,"enrollmentInfo":83,"targetDuration":31,"studyType":86,"phases":87,"briefSummary":89,"conditions":90,"keywords":92,"overallStatus":96,"whyStopped":31,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":106},{"fullName":5,"class":6},"S-INFINITY Pharmaceuticals Co., Ltd","INDUSTRY",[8,14,19],{"label":9,"type":10,"description":11,"interventionNames":12},"Arm 1: Participant Group","EXPERIMENTAL","Participants received XH-S004 20 mg once daily (QD) , for 24 weeks.",[13],"Other: XH-S004 20 mg",{"label":15,"type":10,"description":16,"interventionNames":17},"Arm 2: Participant Group","Participants received XH-S004 40 mg once daily (QD) , for 24 weeks.",[18],"Other: XH-S004 40 mg",{"label":20,"type":21,"description":22,"interventionNames":23},"Arm 3: Participant Group","PLACEBO_COMPARATOR","Participants received the matching placebo once daily (QD) , for 24 weeks.",[24],"Other: Placebo",[26,32,35],{"type":27,"name":28,"description":29,"armGroupLabels":30,"otherNames":31},"OTHER","XH-S004 20 mg","Administered once per day for 24 weeks.",[9],null,{"type":27,"name":33,"description":29,"armGroupLabels":34,"otherNames":31},"XH-S004 40 mg",[15],{"type":27,"name":36,"description":29,"armGroupLabels":37,"otherNames":31},"Placebo",[20],[39,44],{"name":40,"role":41,"phone":42,"phoneExt":31,"email":43},"Jinfu Xu, Doctor degree","CONTACT","86-13321922898","jfxucn@163.com",{"name":45,"role":41,"phone":46,"phoneExt":31,"email":47},"Yinggang Zhu, Doctor degree","86-13917543210","robinzyg-zhu@vip.sina.com",[49],{"facility":50,"status":31,"city":51,"state":52,"zip":53,"country":54,"countryCode":55,"cosmosGeoPoint":56,"geoPoint":61,"contacts":62},"Huadong Hospital Affiliated to fudan univercity","Shanghai","Shanghai Municipality","200040","China","CN",{"type":57,"coordinates":58},"Point",[59,60],121.45806,31.22222,{"lat":60,"lon":59},[63,67],{"name":64,"role":41,"phone":65,"phoneExt":31,"email":66},"Jie Chen","86-13601832090","hdkjc2013@163.com",{"name":68,"role":41,"phone":69,"phoneExt":70,"email":71},"Jie Dong","86-21-62483180","720408","hdhdgcp@163.com",{"type":73,"investigatorFullName":31,"investigatorTitle":31,"investigatorAffiliation":31,"oldNameTitle":31,"oldOrganization":31},"SPONSOR","100591489","phase-2-a-multicenter-randomized-double-blind-placebo-controlled-parallel-group-phase-2-clinical-trial-to-evaluate-the-efficacy-and-safety-of-xh-s004-tablets-in-patients-with-non-cystic-fibrosis-bronchiectasis-100591489",false,"NCT06981091","A Multicenter, Randomized, Double-blind, Placebo-controlled Parallel-group Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of XH-S004 Tablets in Patients With Non-cystic Fibrosis Bronchiectasis","Inclusion Criteria:\n\n1. Understand the procedures and methods of this trial and sign a written informed consent form;\n2. Male or female paticipants aged 18-85 years (inclusive) ;\n3. Chest HRCT shows bronchiectasis affecting one or more lobes, and the condition is clinically diagnosed as non-cystic fibrosis bronchiectasis (clinical manifestations include chronic cough, significant productive cough, and\u002For intermittent hemoptysis, with or without varying degrees of polypnoea and other symptoms);\n4. Based on medical history and the determination of the investigator , participants have at least 2 documented pulmonary exacerbations in the past 12 months before Screening;\n5. Are current sputum producers with a history of chronic expectoration and able to provide a spontaneous sputum sample at screening visit (as described by the patient) ;\n6. The body mass index (BMI) is ≥18 kg\u002Fm2 at screening;\n7. Participants must ensure and agree that from 28 days prior to signing the informed consent form to 28 days after the final administration, women of childbearing potential, male participants, and their partners will use effective contraception methods other than oral drugs (e.g., condoms or intra-uterine contraceptive devices) and will not donate sperm or eggs during this period\n\nExclusion Criteria:\n\n1. Have a primary diagnosis of chronic obstructive pulmonary disease (COPD) or asthma\n2. Have bronchiectasis due to cystic fibrosis (CF), hypogammaglobulinemia, common variable immunodeficiency, or alpha1-antitrypsin deficiency\n3. Are currently being treated for a nontuberculous mycobacterial lung infection, allergic bronchopulmonary aspergillosis, or tuberculosis\n4. Have any acute infections, (including respiratory infections)\n5. Patients who have previously received therapy with DPP1 inhibitors of the same class","ALL","18 Years","85 Years",{"count":84,"type":85},231,"ESTIMATED","INTERVENTIONAL",[88],"PHASE2","The purpose of this study is to find out if XH-S004 can reduce pulmanary exacerbation over a 24-week treatment duration in participants with non-cystic fibrosis bronchiectasis.",[91],"Non-Cystic Fibrosis Bronchiectasis",[93,94,95],"Bronchiectasis","Active neutrophil elastase","Fibrosis","NOT_YET_RECRUITING","2025-05-12",{"date":99,"type":100},"2025-05-20","ACTUAL",{"date":102,"type":85},"2025-05-16",{"date":104,"type":85},"2027-04-28",{"name":5,"class":6},1]